RecruitingPhase 1NCT07006688
A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment
Studying Acquired cystic disease-associated renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Servier Bio-Innovation LLC
- Intervention
- Ivosidenib Oral Tablet(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2028
Study locations (19)
- Emory University, Atlanta, Georgia, United States
- MD Anderson, Houston, Texas, United States
- Icon Cancer Centre, South Brisbane, Queensland, Australia
- Royal Adelaide Hospital, Adelaide, South Australia, Australia
- Hospital de Base de Sao Jose do Rio Preto, São José do Rio Preto, São Paulo, Brazil
- Instituto do Cancer do Estado de Sao Paulo, São Paulo, Brazil
- Fakultni nemocnice v Motole FN Motol, Prague, HlavnÃ- Mesto Praha, Czechia
- University Hospital Brno, Brno, Czechia
- Fakultni nemocnice Ostrava, Ostrava, Czechia
- Vseobecna fakultni nemocnice v Praze, Prague, Czechia
- Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea
- Seoul National University Hospital, Seoul, South Korea
- Severence Hospital, Yonsei University Health Systems, Seoul, South Korea
- Asan Medical Center, Seoul, South Korea
- START - Hospital HM Nou Delfos, Barcelona, Spain
- +4 more locations on ClinicalTrials.gov
Collaborators
Institut de Recherches Internationales Servier
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07006688 on ClinicalTrials.govOther trials for Acquired cystic disease-associated renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06882486Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic TherapyInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- RECRUITINGNANCT06907095Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGNANCT07461090Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost AnalysisMenoufia University
- RECRUITINGPHASE1NCT07195682A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Bristol-Myers Squibb
- RECRUITINGPHASE1, PHASE2NCT07219576Retifanlimab and Ruxolitinib In Solid MalignanciesUniversity of California, San Diego
- RECRUITINGPHASE1, PHASE2NCT07239596Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell CarcinomSuzhou Suncadia Biopharmaceuticals Co., Ltd.
- RECRUITINGNCT07299357Prospective Observational Trial of Image-guided Ablative STereotactic bOdy Radiation Therapy for Primary kidNey Cancer: the STONE TrialIstituto Clinico Humanitas
See all trials for Acquired cystic disease-associated renal cell carcinoma →